Rankings / Weight Loss — Incretins & Amylin
Dulaglutide
Weight loss · GLP-1 agonist
Tier B-
What this is
Primarily a diabetes drug — weight loss effect less than semaglutide/tirzepatide (~3-5%). REWIND trial: 12% MACE reduction in broad T2D population. Primary place is T2D management not obesity pharmacotherapy.
Mechanism
Weekly GLP-1 receptor agonist; same mechanism as semaglutide; approved primarily for T2D
Dose & route
Trulicity: 0.75-4.5 mg SC weekly
Citations
- https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(19)31149-3/fulltext
- https://pubmed.ncbi.nlm.nih.gov/31189511/
- https://www.nejm.org/doi/full/10.1056/NEJMoa2107519
Links go to the source. If a link is dead or you want something re-checked, let me know.
This is an independent synthesis of published research by a non-clinician. Scores are opinions supported by citations, not prescriptions. See the full disclaimer and methodology for how this score was produced and what it does and doesn't mean.